| Ytd | -76.21% | |
| 1y | -88.18% |
| Open | 0.37 | Prev Close | 0.39 | Low | 0.36 | High | 0.37 | Mkt Cap | 8.55M |
| Vol | 232.09K | Avg Vol | 2.12M | EPS | -2.21 | P/E | -0.18 | Forward P/E | N/A |
| Beta | -0.05 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.37 | 200-d Avg | 1.13 | 1yr Est | 7.80 |
MDCX News
Medicus Pharma (NASDAQ:MDCX) earlier this week provided an update on its redesigned clinical study f
Medicus Pharma (NASDAQ:MDCX) earlier this week provided an update on its redesigned clinical study f
Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review B
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enrol
Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review B
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life scie
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life scie
Company's presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gor
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the submission of a key European regulatory
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the submission of a key European regulatory
Medicus Pharma (NASDAQ:MDCX) said Monday it has submitted a Rare Pediatric Disease Designation reque
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the
Medicus Pharma (NASDAQ:MDCX) has submitted an Investigational New Drug application to Abu Dhabi's De
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predic
Medicus Pharma (NASDAQ:MDCX) has submitted an Investigational New Drug application to Abu Dhabi's De
Medicus Pharma (NASDAQ:MDCX) has filed a substantial modification application through the European U
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life scie
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an un
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the filing of a registration study with the
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the filing of a registration study with the
Solidion Technology (NASDAQ:STI) shares added as much as 500% on Thursday after the battery technolo
The filing sets a $1.785 trillion implied market capitalisation at the $135 offer price, but predict
7.16am: FTSE heading lower at open, despite Gulf developments The FTSE 100 could well spend another
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.31) per share which missed the analyst
Medicus Pharma reports dose-response in Phase 2 BCC study, with 200µg cohort showing the strongest e
200μg Cohort Achieves 55% Complete Response at Day 57 Emerging asRegistrational Grade Lead RegimenTh
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estim
Medicus Pharma to present Phase 1 Teverelix data showing dose-dependent estradiol suppression and lo
Medicus Pharma submits Phase 2 design for Teverelix, targeting faster data readouts and lower costs
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.83) per share which missed the analyst
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treate
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treate
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA,
